Role of zinc finger protein 71 in hepatocellular carcinoma: Methodological concerns, clinical relevance, and future directions

Abstract

A recent study by Qin et al emphasized the potential of zinc finger protein 71 (ZNF71) as a promising biomarker for hepatocellular carcinoma (HCC). The authors offered valuable insights into the relationship between ZNF71 and various clinical and pathological stages of HCC. However, several limitations are required to be addressed to improve the findings. These limitations include concerns regarding patient selection, the generalizability of the results, and the necessity for functional validation to establish ZNF71’s specific role in the progression of HCC. Furthermore, statistical issues related to multiple comparisons, confounding variables, and the inherent heterogeneity of high-throughput datasets warrant careful consideration. Future research should focus on multi-institutional cohorts, utilize in vivo models, and compare ZNF71 with established biomarkers to strengthen the clinical relevance of ZNF71.

Keywords: Zinc finger protein 71; Hepatocellular carcinoma; Biomarkers; Genomic data; Prognostic value; Functional validation; Clustered regularly interspaced short palindromic repeats; Tumor progression

Core Tip: A study by Qin et al showed significant upregulation of zinc finger protein 71 (ZNF71) in hepatocellular carcinoma and its association with disease progression. While their findings are valuable, limitations include the need for diverse patient cohorts, larger non-cancerous tissue samples, and functional validation through in vitro and in vivo studies. Statistical improvements, multivariate regression, and multiple comparison corrections are essential. Future research should integrate genomic, epigenomic, and tumor microenvironment data to compare ZNF71 with established biomarkers, such as alpha-fetoprotein. Addressing these gaps will strengthen ZNF71’s potential as a diagnostic and therapeutic target in hepatocellular carcinoma.